Evidence map›Paper›PMID 36262903›Full record

ReviewJournal of community hospital internal medicine perspectives2022

Extracorporeal Liver Support: An Updated Review of Mechanisms and Current Literature.

Anthony Nguyen, Samir Mirza, Nismat Javed, Hamza Hanif, Moon Ryu, Rida Tariq Mirza, Abu Baker Sheikh

Open access · goldAbstract readReview
In one paragraph

Review in Journal of community hospital internal medicine perspectives, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Management of acute liver failure-an updated literature review.World journal of critical care medicine · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Anthony NguyenUniversity of New Mexico Health Sciences Center, Department of Internal Medicine, Allbuquerque, NM, USA.
Samir MirzaDow Medical School, Department of Internal Medicine, Karachi, Pakistan.
Nismat JavedShifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
Hamza HanifUniversity of New Mexico Health Sciences Center, Department of General Surgery, Albuquerque, NM, USA.
Moon RyuUniversity of New Mexico Health Sciences Center, Department of Internal Medicine, Allbuquerque, NM, USA.
Rida Tariq MirzaShifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
Abu Baker SheikhUniversity of New Mexico Health Sciences Center, Department of Internal Medicine, Allbuquerque, NM, USA.
University of New Mexico · USShifa Tameer-e-Millat University · PKDow University of Health Sciences · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acute liver failure is a cause of major mortality in the United States. Although the liver possesses regenerative capabilities, liver transplantation is the mainstay of treating acute liver failure. This modality is associated with many financial and logistic challenges. In this regard, Extracorporeal Liver Support (ECLS) might help in reducing mortality as well as bridge a patient to liver transplant. In some cases, the sequelae of liver failure such as hepatic encephalopathy and multi-organ failure can be postponed long enough for the native liver to self-recover function. With this rationale, we sought to describe the mechanism of various ECLS modalities, provide an overview of the current evidence regarding its use and to highlight future advancements that could overcome hindrances in its use. Methods: A scoping review was performed using PubMed and other databases from 1990 to 2020 with the keywords: 'extracorporeal liver support', 'acute liver failure', 'acute on chronic liver failure', 'albumin dialysis', 'artificial' and 'bioartificial'. Results and conclusions: ECLS has shown significant improvements in bilirubin and urea levels. Various forms of ECLS might also reduce mortality due to liver failure. However, many complications, such as hypotension, anemia, bleeding issues, sepsis, can be anticipated. There are a few barriers to mainstream use of ECLS, such as specific design requirements and high cost that reduce the overall utility of this modality in a small group of liver transplant candidates. Furthermore, a multidisciplinary team approach is required to supervise ECLS, a luxury only available at major academic hospitals. Some advancements for overcoming these barriers include investigation of new scaffolding systems. In order to expand the usage of ECLS, clinical trials focusing on a comparison of different modalities of ECLS with renal replacement therapy in patients with liver failure should be promoted.

Indexed as

Acute liver failureAcute on chronic liver failureAlbumin dialysisArtificial and bioartificialExtracorporeal liver support

Identifiers

PMID36262903
PMCPMC9533802
OpenAlexW4284974339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.